3,5-Bis-perfluorpropyl-1,2,4-triazol | 801-28-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3,5-Bis-perfluorpropyl-1,2,4-triazol
• 英文别名: 3,5-Bis(heptafluoropropyl)-1H-1,2,4-triazole；3,5-bis(1,1,2,2,3,3,3-heptafluoropropyl)-1H-1,2,4-triazole
• CAS: 801-28-5
• 化学式: C₈HF₁₄N₃
• 分子量: 405.094
• InChiKey: FPVIHTFALYNIKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  16

反应信息

• 作为反应物：
  描述：

  3,5-Bis-perfluorpropyl-1,2,4-triazol 在 氘代甲醇-d 作用下， 生成
  参考文献：
  名称：

  Solvolyis reactions of perfluoro-5-aza-4-nonene, C3F7CFNC4F9

  摘要：

  Hydrolysis of the imine perfluoro-5-aza-4-nonene, C3F7-CF=N-C4F9, in ether was studied by several spectroscopic techniques including O-17 NMR. The initial product is C3F7-CO-NH-C4F9 which is converted to (C3F7CO)(2)NH and then to C3F7CONH2 and C3F7CO2H. Solvolysis in liquid ammonia afforded the amidine C3F7-C(=NH)NH2. Reaction with hydrazine produced 3,5-bis(heptafluoropropyl)-1,2,4-triazole whose crystal structure is reported. (C) 2003 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0022-1139(03)00084-8
• 作为产物：
  描述：

  全氟(5-氮杂-4-壬烯) 在 肼 作用下， 以 乙醚 为溶剂， 以28%的产率得到3,5-Bis-perfluorpropyl-1,2,4-triazol
  参考文献：
  名称：

  Solvolyis reactions of perfluoro-5-aza-4-nonene, C3F7CFNC4F9

  摘要：

  Hydrolysis of the imine perfluoro-5-aza-4-nonene, C3F7-CF=N-C4F9, in ether was studied by several spectroscopic techniques including O-17 NMR. The initial product is C3F7-CO-NH-C4F9 which is converted to (C3F7CO)(2)NH and then to C3F7CONH2 and C3F7CO2H. Solvolysis in liquid ammonia afforded the amidine C3F7-C(=NH)NH2. Reaction with hydrazine produced 3,5-bis(heptafluoropropyl)-1,2,4-triazole whose crystal structure is reported. (C) 2003 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0022-1139(03)00084-8

文献信息

• Renal-selective biphenylalkyl 1H-substituted-1, 2, 4- triazole angiotensin I I antagonists for treatment of hypertension
  申请人：G.D. Searle & Co.,

  公开号：US20040220245A1

  公开（公告）日：2004-11-04

  Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole compounds, of which N-acetylglutamic acid, 5-[[4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]]carbonylhydrazide, (shown below) is an example: 1

  本文描述了一种肾选择性化合物，其中，在一种实施例中，这些前药被优先转化为能够阻断血管紧张素II（AII）受体的化合物。这些前药是由两个组分形成的结合物，即由AII拮抗剂化合物提供的第一组分和当两个组分在结合物中化学连接时能够被从第一组分中裂解的第二组分。这两个组分通过一种在肾脏中有选择性的键进行化学连接，例如，通过一种酶。释放的AII拮抗剂化合物随后可用于阻断肾脏内的AII受体。特别感兴趣的结合物是双苯甲基1H-取代-1,2,4-三唑化合物的谷氨酰衍生物，其中N-乙酰谷氨酸，5-[[4'-(3,5-二丁基-1H-1,2,4-三唑-1-基)甲基][1,1'-联苯基]-2-基]甲酰肼（如下图所示）是一个例子：1
• Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonists for treatment of hypertension
  申请人：G.D. Searle & Co.

  公开号：US20040121989A1

  公开（公告）日：2004-06-24

  Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole compounds, of which N-acetylglutamic acid, 5-[[4′-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1′-biphenyl]-2-yl]]carbonylhydrazide, (shown below) is an example: 1

  本文描述了肾脏选择性化合物，其中，在一种实施例中，这些前药被优先转化为能够阻断血管紧张素II（AII）受体的化合物。这些前药是由两个组分形成的共轭物，即由AII拮抗剂化合物提供的第一组分和当两个组分在共轭物中化学连接时能够被剪切的第二组分。这两个组分通过一种键化学连接，该键在肾脏中被选择性地剪切，例如，通过一种酶。释放的AII拮抗剂化合物随后可用于阻断肾脏内的AII受体。特别感兴趣的共轭物是双苯甲基1H-取代-1,2,4-三唑化合物的谷氨酰衍生物，其中N-乙酰谷氨酸，5-[[4′-[(3,5-二丁基-1H-1,2,4-三唑-1-基)甲基] [1,1′-联苯] -2-基] -羧酰肼（如下图所示）是一个例子：1
• Toluene-Sandwiched Trinuclear Copper(I) and Silver(I) Triazolates and Phosphine Adducts of Dinuclear Copper(I) and Silver(I) Triazolates
  作者：H. V. Rasika Dias、Shreeyukta Singh、Charles F. Campana

  DOI：10.1021/ic800396t

  日期：2008.5.19

  Cu (I) and Ag (I) complexes of the fluorinated triazolate ligand [3,5-(C3F7)2Tz](-) have been synthesized using the corresponding metal(I) oxides and the triazole. They form pi-acid/base adducts with toluene, leading to [Tol][M3][Tol] ([Tol]=toluene; [M3]=[3,5-(C3F7)2Tz]Cu}3 or [3,5-(C3F7)2Tz]Ag}3) type structures. Packing diagrams show the presence of extended chains of the type [Tol][M3][Tol]}infinity

  氟化三唑酸酯配体[3,5-（C3F7）2Tz]（-）的Cu（I）和Ag（I）配合物已使用相应的金属（I）氧化物和三唑合成。它们与甲苯形成pi-酸/碱加合物，生成[Tol] [M3] [Tol]（[Tol] =甲苯； [M3] = [3,5-（C3F7）2Tz] Cu} 3或[ 3,5-（C3F7）2Tz] Ag} 3）型结构。堆积图显示存在[Tol] [M3] [Tol]}无穷大类型的延伸链，但是对于显着的π-芳烃/π-芳烃接触，甲苯间环距离太长。这些三氮杂铜和银与PPh3（金属离子/ P摩尔比为1：1）反应，生成双核[3,5-（C3F7）2Tz] Cu（PPh3）} 2和[3,5-（ C3F7）2Tz] Ag（PPh3）} 2。它们的特征是具有船形的六元Cu（mu-NN）2Cu或Ag（mu-NN）2Ag核。
• [EN] 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
  申请人：G.D. SEARLE & CO.

  公开号：WO1991017148A1

  公开（公告）日：1991-11-14

  (EN) A class of 1H-substituted-1,2,4-triazole compounds is described for use in treatment of circulatory disorders, especially cardiovascular disorders. Compounds of interest are angiotensin II antagonists of formula (II), wherein R1 is selected from hydroxy, formyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, carboxyethyl, phenyl, benzyl, phenethyl, cyclopentyl, cyclohexyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, adamantyl, adamantylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, dimethoxymethyl, diethoxymethyl, 1,1-dimethoxypropyl, 1,1-dimethoxybutyl, 1,1-dimethoxypentyl, hydroxypropyl, halo, monofluoromethyl, difluoromethyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-difluorobutyl, 1,1-difluoropentyl, pentafluoroethyl, heptafluoropropyl, phenylacetyl, phenyldifluoroethyl, aminomethyl, aminoethyl, aminopropyl, acetylaminomethyl, t-butoxycarbonylaminoethyl, glutamic acid methyl ester and glutamic acid ethyl ester; wherein R2 is selected from carboxyethyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl and neopentyl; wherein each of R3 through R11 is hydrido with the proviso that at least one of R5 and R9 must be selected from COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, (III), (IV) and (V), wherein each of R40 and R41 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.(FR) L'invention concerne une classe de composés de 1,2,4-triazole à substitution 1H utilisés dans le traitement de troubles circulatoires, notamment de troubles cardiovasculaires. Les composés d'intérêt sont des antagonistes d'angiotensine II de la formule (II), dans laquelle R1 est choisi parmi hydroxy, formyle, méthyle, éthyle, n-propyle, isopropyle, n-butyle, sec-butyle, isobutyle, tert-butyle, 4-méthylbutyle, n-pentyle, néopenthyle, n-hexyle, n-heptyle, n-octyle, n-nonyle, carboxyéthyle, phényle, benzyle, phénéthyle, cyclopentyle, cyclohexyle, cyclopentylméthyle, cyclohexylméthyle, cyclohexyléthyle, cyclohexylpropyle, adamantyle, adamantylméthyle, 1-oxoéthyle, 1-oxopropyle, 1-oxobutyle, 1-oxopentyle, diméthoxyméthyle, diéthoxyméthyle, 1,1-diméthoxypropyle, 1,1-diméthoxybutyle, 1,1-diméthoxypentyle, hydroxypropyle, halo, monofluorométhyle, difluorométhyle, 1,1-difluoroéthyle, 1,1-difluoropropyle, 1,1-difluorobutyle, 1,1-difluoropentyle, pentafluoroéthyle, heptafluoropropyle, phénylacétyle, phényldifluoroéthyle, aminométhyle, aminoéthyle, aminopropyle, acétylaminométhyle, t-butoxycarbonylaminoéthyle, ester méthylique d'acide glutamique et ester éthylique d'acide glutamique; dans laquelle R2 est choisi parmi carboxyéthyle, éthyle, n-propyle, isopropyle, n-butyle, sec-butyle, isobutyle, 4-méthylbutyle, tert-butyle, n-pentyle et néopentyle; dans laquelle R3 à R11 représentent chacun hydrido à condition que R5 et/ou R9 soient choisis parmi COOH, SH, PO3H2, SO3H, CONHNH2, CONHNHSO2CF3, OH, les formules (III), (IV) et (V), dans lesquelles R40 et R41 sont chacun indépendamment choisis parmi chloro, cyano, nitro, trifluorométhyle, méthoxycarbonyle et trifluorométhylsulfonyle. Ces composés sont particulièrement utiles dans le traitement ou la maîtrise de l'hypertension et de l'insuffisance cardiaque.

  一种描述用于治疗循环系统疾病（特别是心血管疾病）的1H-取代的1,2,4-三azole化合物的类群的英文文本已被翻译。这些化合物的分子式为： **图2-2** 的化合物（其中 **R1** 精选自以下基团：**羟基、甲氧基、甲基、乙基、n-丙基、isopropyl、n-butyl、sec-butyl、isobutyl、tert-butyl、4-methylbutyl、n-pentyl、neopentyl、n-hexyl、n-heptyl、n-octyl、n-nonyl、carboxyethyl**，此外还包括 **phenyl、benzyl、phenethyl、cyclopentyl、cyclohexyl、cyclopentylmethyl、cyclohexylmethyl、cyclohexylethyl、cyclohexylpropyl、adamantyl、adamantylmethyl、1-oxoethyl、1-oxopropyl、1-oxobutyl、1-oxopentyl、dimethoxymethyl、diethoxymethyl**，以及其他基团。 **R2** 精选自 **carboxyethyl、ethyl、n-propyl、isopropyl、n-butyl、sec-butyl、isobutyl、4-methylbutyl、tert-butyl、n-pentyl 和 neopentyl**。 从 **R3** 到 **R11**，每个基团都是 **hydrido** 模式，但 **R5** 和 **R9** 必须至少从以下基团中选择一者：**COOH、SH、PO3H2、SO3H、CONHNH2、CONHNHSO2CF3、OH、(III)、(IV) 和(V)**。 **R40** 和 **R41** 独立地从以下基团中选择：**chloro、cyano、nitro、trifluoromethyl、methoxycarbonyl 和 trifluoromethylsulfonyl**。 这些化合物特别适用于治疗高血压和心力衰竭等心血管疾病。
• ——
  作者：G. G. Furin、Ki-Wan Chi、N. I. Protsuk、V. A. Lopyrev

  DOI：10.1023/a:1013876707892

  日期：——

  The reaction of perfluoro(5-aza-4-nonene) with hydrazine hydrate in tetrahydrofuran at 0-20degreesC in the presence of triethylamine yields 2,5-bis(heptafluoropropyl)-1H-1,2,4-triazole; under similar conditions perfluoro(5-aza-4-nonene) reacts with arylhydrazines to form 1-aryl-3,5-bis(heptafluoropropyl)-1,2,4-triazoles.